Zoetis Inc. (NYSE: ZTS) — The Untouchable Compounder, Marked Down to Its Cheapest Price Ever

Independent Equity Research Note Date: 2026-06-19 | Price: $78.71 (2026-06-18) | Market cap: ~$32.4B | EV: ~$39.7B

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The rest of this article is deliberately written position-free; the single call and valuation zone in this piece appear only inside this clearly-labeled block.

Call: BUY / accumulate-on-weakness. Conviction: medium-high. This is the inverse of the more common setup today — a great business trading at its richest-ever multiple, where the right move is to wait. Zoetis is a genuinely wide-moat, ~24%-ROIC, 72%-gross-margin animal-health franchise — the single highest-quality asset in its sub-industry — that has been marked down to the cheapest valuation of its entire public life: ~13x trailing / ~11x forward earnings, ~9.8x EV/EBITDA, the 1.2nd percentile of its own 13-year multiple history, after a ~67% drawdown from its $235 peak. The market has re-underwritten ZTS from “untouchable secular compounder” to “broken, ex-growth specialty-pharma value trap.” My read is that the truth sits in between and is mispriced toward the pessimistic end: growth genuinely decelerated (US companion-animal demand softened and competition stepped up structurally in dermatology and parasiticides for the first time), but the moat, the returns on capital, the margins, and the cash generation are all intact and at record levels — this is a revenue-growth scare, not a returns impairment.

The framing is fallen-quality / contrarian-value, and I want to be honest that the tape has not confirmed: the factor model classifies ZTS as a low-beta (0.7–0.85), positive-Quality name whose nearest neighbors are wide-moat and min-vol ETFs (VanEck MOAT, USMV) — not a high-beta blow-up — yet relative strength is −51% over 12 months and the stock was still making lower lows into mid-June. So this is a knife that has not visibly stopped falling, which is exactly why you accumulate in tranches rather than back up the truck. My entry zone is ~$70–85 (roughly 10–12x forward EPS / 9–10x EV/EBITDA — i.e. paying a structural-decliner multiple for a business that still out-earns its cost of capital ~3x over), scaling harder toward the $65–75 band the May capitulation and the bear case ($60–75) define, where the downside is largely realized and you are handed the secular re-acceleration optionality and the entire mAb/parasiticide pipeline for free. Three directors — including the Chairman — bought the open market at $75–78 in May; that is the only insider conviction signal I weight, and it is on my side. Flips bullish (conviction high): two consecutive quarters of stabilizing-to-positive US companion-animal organic growth with gross margin held ≥70% — proof the stall was an air-pocket. Flips bearish: US companion organic stays ≤LSD for 3–4 more quarters and gross margin cracks below ~70%, confirming pricing power is structurally broken and 13x is fair, not cheap. Tag: the best house on the block, finally on the clearance rack — buy the quality, respect the knife.

📈 Stock Price Action — Five-Year Event Map

Factual price history with attributed drivers — not a recommendation. Price moves are Fact; attributed causes are Interpretation. Built from the AZI five-year price series, cross-referenced to earnings prints, 8-K events, and dated news.

Over five years ZTS round-tripped from a pandemic-era darling to a deep-drawdown contrarian. The arc in plain numbers: a $235.44 all-time-high close (Dec-29-2021) → a rate-driven de-rate to ~$126 (late-2022) → a recovery to ~$194 (early-2024) → a long grind lower through 2025 → two violent earnings-day crashes (Nov-2025 and May-2026) that took it to a 52-week and multi-year low of $74.22 (May-15-2026). It now trades $78.71, ~40% below its 2026 high of $130.53, ~33% below its 200-day EMA (~$117), and ~67% below the all-time high — the deepest drawdown of its public life.

Cycle narrative. Events 1–2 are macro: ZTS was a ~44x-P/E pandemic compounder that the 2022 rate shock de-rated like every other long-duration growth name — a multiple event, not a business event. Events 3–4 were the business reasserting itself (the Librela/Solensia osteoarthritis-pain franchise launched, derm and parasiticides grew double-digit) before the first cracks appeared: softening US vet visits and the emerging FDA adverse-event file on Librela. Events 5 and 7 are the heart of this memo. On Nov-4-2025 the company cut its full-year revenue guide and — for the first time in its public life — conceded that therapeutic vet visits had fallen for three straight quarters and that competition in its two largest companion franchises was intensifying; the market began re-rating ZTS from “immune compounder” to “cyclically and competitively exposed.” On May-7-2026 it missed and cut the brand-new FY2026 guide just three months after issuing it, with US companion animal −11%, dermatology −13%, and Librela −22%, and management abandoned its “competition is normal/transitory” framing in favor of a defensive cost program. The stock lost a fifth of its value in a day and bottomed at $74. Event 9 — three directors, including the Chairman, buying stock in the open market at $75–78 — is the first contrarian signal, but momentum has not yet turned.

1. Executive Summary

Zoetis is the world’s largest pure-play animal-health company — a 2013 spin-out of Pfizer’s animal-health division, headquartered in Parsippany, NJ — with FY2025 revenue of $9.47B, a 71.8% gross margin, a 38.0% operating margin, ~24% return on invested capital, and ~$2.3B of free cash flow. By any measure of business quality it is exceptional: a decade-plus of 18–24% ROIC, gross margin that has risen from 68% to a record 72%, the broadest product portfolio in the industry (~300 product lines across eight core species), and the #1 share of the companion-animal medicines market (~28%). It operates in a structurally attractive sub-industry — animal health is cash-pay (no insurer, no PBM, no government price-setter), enjoys faster and cheaper regulatory approvals than human pharma, and has historically suffered far weaker generic erosion because the prescribing vet, not a formulary, chooses the brand.

And yet the stock has been one of the worst large-cap performers in healthcare: down ~67% from its $235 all-time high (Dec-2021) to $78.71, with two violent earnings-day crashes (−13.8% on Nov-4-2025, −21.5% on May-7-2026) that bottomed at $74.22 in May. The cause is not a collapse in profitability — margins and ROIC are at record highs — but a collapse in growth and in the multiple the market will pay for it. Revenue growth decelerated from +8.3% (2024) to +2.3% reported (2025), and Q1-2026 came in roughly flat organically (−5% underlying, masked by a ~$100M fiscal-calendar shift). The deceleration is driven by a genuine, twin development: (1) a cyclical softening in US companion-animal demand (fewer vet visits, more price-sensitive owners post the pandemic pet-boom), layered on (2) the first real structural step-up in competition in ZTS’s two largest companion franchises — dermatology (Apoquel facing Elanco’s Zenrelia and a new Merck IL-31 monoclonal antibody) and parasiticides (Simparica facing Credelio Quattro and NexGard Plus) — plus generics finally biting older blockbusters (Convenia, Cerenia) and a safety/adverse-event overhang on the Librela osteoarthritis-pain franchise.

The result is a rare valuation: ZTS trades at the 1.2nd percentile of its own 13-year valuation history (P/E 0.5th pctile, P/S 0.5th pctile) — ~13x trailing earnings, ~9.8x EV/EBITDA, ~4.2x EV/sales. It is now cheaper on EV/EBITDA than levered, 6%-margin Elanco, sub-scale Phibro, and even big-pharma Merck, and roughly one-third of best-in-class IDEXX. The central question of this memo is whether that re-rating is correct (a structurally ex-growth business worth a structural-decliner multiple — the value-trap case) or an overshoot (a temporary growth air-pocket in an intact wide-moat compounder — the fallen-quality case). The evidence points toward overshoot on the business and genuine-but-bounded risk on the growth: returns on capital have not eroded, the moat’s durable core (scale, R&D, portfolio breadth, manufacturing, mAb first-mover position) is intact, and the company is a disciplined organic compounder — but pricing power is being tested at the edges for the first time, two guidance cuts in six months have shredded management credibility, and the growth-product patents (Apoquel ~2029, Simparica Trio ~2032) carry real loss-of-exclusivity risk this decade. This memo lays out both sides without a recommendation; the position is taken only in Claude’s Take above.

2. Business Overview

What the company does. Zoetis discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostics, and related products for animals. It is the direct descendant of Pfizer’s animal-health business (roots back to 1952), spun out via IPO in February 2013. It is the largest pure-play in the global animal-health industry, with ~$9.5B in revenue, operations in ~45 countries, and roughly 14,000 employees (including ~1,700 in R&D).

How it makes money. Zoetis sells branded, largely patent-protected animal-health products into two end-markets, organized as two reportable segments and two species groupings:

• Companion animal (~70% of revenue; $6,587M in 2025): dogs, cats, and horses. This is the growth engine and the source of the premium franchise. Key product lines: dermatology (Apoquel and Cytopoint for atopic dermatitis/itch), parasiticides (the Simparica and Simparica Trio flea/tick/heartworm combinations), osteoarthritis-pain monoclonal antibodies (Librela for dogs, Solensia for cats), vaccines, and an emerging diagnostics franchise.
• Livestock (~30% of revenue; $2,764M in 2025): cattle, swine, poultry, fish, and sheep. A mature, GDP-/protein-cycle-linked business — vaccines, anti-infectives, parasiticides, and (until divested in 2024) medicated feed additives. Lower-growth and more price-competitive, but a meaningful diversifier and, after the 2024 medicated-feed-additive (MFA) divestiture, a higher-margin, vaccine-led mix.

By reportable segment, the split is US ($5,097M in 2025, ~54%) and International ($4,254M, ~45%), plus a small contract-manufacturing/human-health line ($116M).

Revenue by product category (FY2025, Fact, 10-K): Parasiticides $2,341M, Vaccines $1,959M, Dermatology $1,754M, Anti-infectives $1,036M, Pain & sedation (incl. OA-pain mAbs) $840M, Other pharmaceuticals $697M, Diagnostics $434M, Other non-pharma $263M, Medicated feed additives $27M (post-divestiture).

Recurring vs. non-recurring. Revenue is highly repeatable rather than contractually recurring: chronic-condition products (Apoquel for lifelong itch, Librela for chronic OA pain, monthly parasiticides) generate durable, refill-driven demand, and vaccines/livestock products are consumed on a regular cycle. There is no subscription model, but the prescription/dispensing habit of the veterinarian — who chooses the brand and often dispenses it from the clinic — creates a powerful, sticky, repeat-purchase dynamic. Roughly 42% of revenue comes from the top five product lines (Simparica franchise ~16%, Apoquel ~12%, plus Cytopoint, Librela, and the ceftiofur anti-infective line), which is meaningful concentration and a key durability watch-item.

Verdict. A high-quality, high-margin, repeat-purchase branded-products business with a genuinely diversified portfolio across species, geographies, and therapeutic categories — but with revenue concentration in a handful of companion-animal blockbusters whose competitive and patent dynamics now matter more than they did a year ago.

3. Industry Dynamics

Structure and size. The global animal-health market is roughly $45–65B depending on definition (the core medicines/vaccines/parasiticide/dermatology pool ZTS competes in is ~$45–55B; broader figures add diagnostics, equipment, and feed additives). It is a consolidated oligopoly: the top five players — Zoetis, Merck Animal Health, Boehringer Ingelheim Vetmedica, Elanco, and IDEXX (diagnostics) — hold ~40% of the total, and ZTS alone holds ~28% of companion-animal medicines. Companion animal is the larger and historically faster-growing pool; livestock is the mature, protein-cycle-linked, price-competitive half.

Why this is widely considered the best sub-sector in healthcare — pressure-tested. Four structural features genuinely distinguish animal health from human pharma, and they are real:

1. Cash-pay, no third-party reimbursement, no PBMs. Pet owners and livestock producers pay out of pocket. There is no insurer or government price-setter and no pharmacy-benefit-manager rebate machine. This is the single biggest structural advantage over human pharma — it preserves pricing power and avoids the reimbursement cliff. But it cuts both ways: cash-pay demand is discretionary and price-elastic, which is exactly what surfaced in 2025–26 as price-sensitive owners deferred vet visits and traded down. A reimbursed human drug does not have this cyclicality; an animal-health drug does.
2. Faster, cheaper approvals. The FDA Center for Veterinary Medicine, USDA (biologics/vaccines), and EMA approve animal drugs far faster and more cheaply than human NDAs — no large Phase III human trials. This yields high R&D productivity: ZTS spends ~7.4% of sales (~$700M) on R&D versus 15–20%+ for human pharma, for a comparable cadence of launches.
3. Historically weak generic erosion. Animal-health brands have historically held share for years-to-decades after patent expiry because the generic-substitution machinery of human pharma — mandatory substitution laws, PBM formularies, large generic houses — does not exist in the vet channel. The vet recommends and often dispenses by brand. This is the industry’s deepest structural moat — and 2025–26 is the first real stress-test of it (generics took meaningful share from Convenia and Cerenia, and branded competition is discounting hard against Apoquel).
4. The agency relationship. The buyer (owner) is not the chooser (vet). The vet’s brand habit and clinic-dispensing economics create durable pricing power — the classic Greenwald/Marathon “agent recommends, customer follows” dynamic.

Distribution and the channel shift. Three channels: veterinary clinics (the core, where the detailing/relationship moat lives), corporatized vet chains (Mars Veterinary Health — VCA/Banfield/BluePearl — is the largest; corporate/PE-owned share of US practices has risen from ~8% in 2011 to ~50% in 2025), and retail/e-commerce (Chewy, Amazon, direct-to-owner). Channel consolidation is a double-edged sword for ZTS: corporatized buyers and e-commerce price transparency increase buyer power and accelerate price competition — precisely the dynamic now showing up as “price-driven competitive pressure” on Apoquel.

Capital cycle (Marathon lens). The industry sits in a late-boom / early-supply-response phase. A decade of ZTS’s ~24% ROIC and 30–40x multiples attracted exactly what the capital cycle predicts: capital and capacity flooding into the high-return companion-animal niches. The supply response is visible — Elanco’s Zenrelia (derm) and Credelio Quattro (parasiticide) blockbuster launches in 2024–25, Boehringer’s NexGard Plus, a forthcoming Merck IL-31 mAb in derm, and generics finally arriving on older blockbusters. High returns are doing what high returns do: attracting the capital that erodes them. Crucially, this is not a heavy-capex overcapacity cycle (animal health is asset-light, ~3–4% capex/sales); the “capital” flooding in is R&D and competitive product launches, which erode returns through share and price competition rather than physical glut.

Verdict: structurally GOOD, but less impregnable than consensus believed, and currently in the down-leg of its first real competitive/capital cycle. The cash-pay/no-PBM/no-mandatory-substitution structure is genuinely superior to human pharma and supports above-average through-cycle economics — the “best sub-sector in healthcare” claim is directionally correct. But two consensus errors are being corrected in real time: demand is discretionary and cyclical, not recession-proof; and the historically weak generic/competitive erosion is finally arriving as a decade of supernormal returns pulls in competitive supply. Good industry, mid-cycle — not a perpetual-compounding machine.

4. Competitive Position

The moat is real, wide, and ROIC-validated — and narrowing at the edges for the first time.

Moat type (Greenwald taxonomy). Zoetis’s advantage is a combination, weighted toward the durable kinds:

• Economies of scale + customer captivity (the strongest, per Greenwald). ZTS is #1 with ~28% of companion-animal medicines and the broadest portfolio (~300 product lines, eight species). It runs the largest dedicated veterinary salesforce/detailing organization and the largest manufacturing/supply base in the industry. Scale plus the vet’s brand captivity is the self-reinforcing loop. Greenwald’s caveat applies: scale advantages must be defended move-for-move and erode with any share loss — which is exactly what is now being tested.
• Intangibles / brand (vet-prescribed agency brand). Apoquel, Simparica, Librela, and Cytopoint are brand-prescribed; owners follow. Durable but product-specific, not portfolio-wide, and weakening as Mars/Chewy raise price transparency.
• Switching costs (modest) and distribution (real). Clinic formulary/protocol habit and dispensing economics create real but low switching friction — a vet can move a dog from Apoquel to Zenrelia at the next visit, and on price some are doing so. The entrenched clinic relationships are a genuine distribution advantage a new entrant cannot replicate quickly, but corporatization erodes it.

Greenwald tests.

• ROIC durability — PASSES decisively. ROIC has held 18–24% for a decade-plus (23.6% in 2025), with gross margin rising from 68% to 72%. Sustained ROIC roughly 3x the ~8% cost of capital is unambiguous evidence of a real, durable advantage. Critically, ROIC has not yet deteriorated — the 2025 stall is a revenue-growth event, not a returns event.
• Market-share stability — PASSES historically, now under stress. ZTS held #1 / ~28% companion share for years (Greenwald’s <2% drift test). But Q1-2026 showed the first cracks: key dermatology −11%, Apoquel under price pressure, Simparica −1% globally (US Simparica −8%). This is the share-erosion signal Greenwald warns is fatal to a scale moat if it compounds — so the next 4–6 quarters of US companion share and ROIC data are decisive.

Head-to-head competitor map.

The moat-erosion stress test.

• Dermatology (the historic ~$1.75B engine). Elanco’s Zenrelia (a once-daily JAK launched Sept-2024) claims head-to-head superiority to Apoquel and has been promoted aggressively on price; a Merck IL-31 monoclonal antibody is approaching US approval (already launched in the EU). Apoquel’s main US compound patent expires ~2029 (the Apoquel Chewable formulation carries fresh patents extending much later — classic life-cycle management). By Q1-2026 derm was −11% globally, with price the primary battleground. This is the clearest evidence the moat is narrowing, not theoretical.
• Parasiticides (the current ~$2.3B category / ~$1.5B Simparica franchise). Elanco’s Credelio Quattro (Jan-2025, “broadest” coverage, already a blockbuster) and Boehringer’s NexGard Plus are direct combination-parasiticide attacks. US Simparica Trio was −8% in Q1-2026, losing new-patient starts as vet traffic fell. Simparica Trio’s core patent runs to ~2032 — better protected than Apoquel — but the pool ZTS used to dominate is fragmenting.
• OA-pain monoclonal antibodies (Librela/Solensia). Here ZTS has a genuine first-mover/biologic lead (mAbs are hard to copy — a real durability positive), but the franchise is impaired by a safety/adverse-event controversy: the FDA’s CVM logged ~3,674 adverse-event reports associated with Librela (including 800+ death reports) by 2024, issued a veterinarian alert in late 2024, and label updates are ongoing. Librela revenue fell every quarter through 2025 (US −22% in Q1-2026, though management claims the first sequential US uptick in six quarters). The biologic moat is real; the execution/safety damage is partly self-inflicted, and the long-acting follow-ons (Lenivia, with US approval expected ~2027; Portela for cats) are the recovery bet.

Verdict: a genuine, wide moat (scale + agency-brand captivity + distribution) that is real and ROIC-validated, but is narrowing at the growth-product edges for the first time in the company’s public life. The durable core — manufacturing/R&D scale, #1 portfolio breadth, mAb first-mover position, a decade of 20%+ ROIC — is intact and not in question. What has changed is that the growth-engine products (Apoquel, Simparica) now face credible, sometimes-superior competition into a softening, price-sensitive, corporatized-buyer channel. This is a moat being defended, not breached — but Greenwald is explicit that scale moats die by exactly this slow share/price leakage, so the next several quarters of share and ROIC data are the verdict.

5. Growth History and Forward Opportunities

History. Zoetis compounded revenue from $6.26B (2019) to $9.47B (2025), a ~7% reported CAGR (high-single-digit operationally, ex-FX), with EPS growing faster ($3.14 to $6.02 diluted) on margin expansion and buybacks. Growth was high-quality and overwhelmingly organic — driven by new-product launches (the Simparica franchise, the derm franchise, the Librela/Solensia mAbs) and price, not acquisitions. The cadence: +16.4% (2021, pandemic boom), +3.9% (2022, FX-hit), +5.4% (2023), +8.3% (2024), +2.3% (2025).

The deceleration is the story. The drop from +8.3% (2024) to +2.3% reported / ~+6% operational (2025), and to roughly flat organically in Q1-2026, is overwhelmingly a US companion-animal phenomenon: US revenue grew +11% in 2024 then went flat (~0%) in 2025, and US companion animal was −11% in Q1-2026. The drivers, in order: (1) softer US vet-clinic traffic and more price-sensitive pet owners (a demand/cyclical effect — fewer therapeutic visits for three-plus straight quarters); (2) the structural step-up in competition on derm and parasiticides; (3) the Librela safety overhang stalling the prior breakout franchise (Pain & sedation went +41% in 2024 to −1% in 2025); and (4) a chronic ~1–3-point FX headwind. International (+10% operational in Q1-2026) and livestock (+12% operational) held up, partially offsetting US companion weakness.

A quality-of-disclosure flag. A fiscal-year-alignment change (eliminating a one-month reporting lag for ex-US subsidiaries) shifted ~$100M of International revenue out of Q4-2025 into early 2026 — which flattered the Q1-2026 headline (reported “flat” organic) versus the true ~−5% underlying decline management itself disclosed on the call. The underlying quarter was weaker than the headline, and the calendar change muddied comparability at exactly the wrong moment for credibility.

Forward opportunities.

• Companion-animal normalization. The bull case rests on US vet traffic and owner spending normalizing as the post-pandemic demand air-pocket passes; pet medicalization remains a multi-decade secular tailwind.
• Parasiticides. Simparica Trio (patent to ~2032) with label extensions, defending share against the new combination entrants.
• OA-pain mAb recovery. Stabilizing Librela (management claims a sequential US inflection) and launching the long-acting follow-ons (Lenivia US ~2027, Portela) — a genuine biologic franchise that is hard to replicate if the safety narrative is managed.
• Diagnostics ($434M, +12%). Sub-scale versus IDEXX’s ~$4.3B but a stated growth priority and a structurally attractive razor/razorblade adjacency.
• International + livestock. A higher-margin, vaccine-led livestock mix post-MFA divestiture and double-digit international companion growth.

Verdict: historically high-quality (organic, margin-accretive) growth that has decelerated sharply and is now of uncertain quality. The forward opportunities are real and multiple, but the near-term growth algorithm — long marketed as a durable ~8% — has visibly broken to low-single-digits, and whether it re-accelerates to mid-single-digit-plus is the single most important open question in the thesis.

6. Financial Quality

Among the best financial profiles in healthcare — and the quality is not what broke.

Margins and operating leverage (Fact, ROIC/10-K).

The single most important positive finding: operating leverage is still intact despite the revenue stall. In 2025, on only +2.3% revenue, operating income grew +6% and operating margin expanded ~140bps to a record 38.0%; gross margin hit a record 71.8% (COGS actually fell in dollars, on favorable mix toward high-margin companion pharma, lower inventory charges, and the MFA exit). Pricing growth ran ~4% in 2025. This is the signature of a business that still has pricing power and converts modest top-line into superior margin and EPS expansion — the opposite of a franchise in distress.

Cash generation and quality of earnings (Fact).

Earnings are clean. Operating cash flow tracks or exceeds net income in four of five years (five-year cumulative OCF ~$12.3B vs NI ~$11.7B, ratio ~1.05x); the 2022 dip (0.90x) was a deliberate inventory build during a capacity ramp, which normalized. Capex peaked at $732M (2023, ~8.6% of sales) during a manufacturing build-out and is now declining toward D&A (~$490M), so FCF conversion should structurally improve. One-time items are immaterial — asset impairments run $30–50M/yr; the only notable discrete event is the 2024 MFA divestiture (~$293M proceeds, low-margin), which depressed reported 2025 livestock growth but barely touched earnings. FY2025 GAAP NI of $2,673M reconciles to ~$2,847M adjusted — a modest ~$174M of intangible amortization and purchase accounting, small versus peers. There is no NI-vs-cash divergence and no aggressive accounting to flag.

Balance sheet (Fact). Cash ~$2.3B, total debt $9.24B, net debt ~$6.7B; net debt/EBITDA ~1.65x (up from ~1.2x as the company deliberately levered to fund buybacks); EBITDA/interest ~18x. Rated A3 (Moody’s, upgraded Jan-2025) / BBB+ (S&P, upgraded 2025), both stable — ratings upgrades through the leverage-up, confirming the debt is conservative. Liquidity is ample (current ratio ~3x, undrawn $1.25B revolver). Book equity has fallen ($4.8B → $3.3B) purely from treasury-stock buybacks (~$10.7B cumulative), so P/B (~10x) and tangible book are not meaningful metrics for this cash-generative branded-pharma — ignore them.

ROIC/ROE rigor. ROIC ~24% (2025) is real, not flattered. Goodwill + net intangibles are ~$3.8B of $15.5B total assets (~24%) — low for a large pharma, because ZTS grows organically rather than by big M&A (the lone $2B Abaxis deal is well-seasoned). The high return is earned on a lightly-acquired, organically-built capital base — genuine pricing power and capital efficiency, not a goodwill-deflated denominator. Even on gross invested capital including all intangibles, ROIC stays comfortably double-digit and well above WACC.

Share count and dilution (Fact). Diluted shares fell from 481.8M (2019) to 443.8M (2025), a ~7.9% net reduction. Crucially, SBC is tiny (~$83M, <0.9% of revenue), so buybacks are net share-shrinking, not dilution-offsetting — the opposite of most large-caps.

Verdict: quality of earnings is high and economics DO improve with scale — even through the revenue stall. Record margins on flat revenue, clean ~1.05x cash conversion, a genuine ~24% ROIC on a lightly-acquired base, an investment-grade balance sheet, and net-accretive buybacks. The caveats are all top-line, not quality: growth has decelerated, revenue is concentrated (top-five lines ~42%), FX is a chronic drag, and the company is levering modestly to sustain returns. The business’s financial quality is not in question; its growth is.

7. Capital Allocation

Mostly excellent — with one clear, expensive mistake.

M&A — a disciplined organic grower, not an empire-builder. Over a decade-plus, only one deal exceeded $1B:

This is a textbook disciplined-reinvestment profile (favorable on the Marathon lens — no high-return-chasing asset-growth binge that mean-reverts). M&A is a rounding error versus capital returned; there is no peak-multiple mega-deal. R&D intensity (~7.4%, the highest sustained in animal health) is the highest-quality reinvestment ZTS makes and the true moat-builder.

Buybacks — the weakest link.

The 2025 buyback ($3.24B, ~3x the 2023 pace) exceeded full-year FCF; combined with dividends, ~$4.1B of returns exceeded FCF, funded partly by incremental debt (a Dec-2025 convertible offering specifically funded a $1.75B repurchase). The company deployed record dollars buying its own stock at ~$160–180 — near all-time-high ~30–35x multiples — immediately before a ~67% collapse to ~$79. This is a substantial, valuation-insensitive misallocation that destroyed near-term per-share value, and the share-shrink (~1.5%/yr) is modest for the dollars deployed because the buy price was so high. The silver lining: the dividend and balance sheet give the company every ability to repurchase now, counter-cyclically, at the cheapest multiple in its history — the single capital-allocation action to watch.

Dividend. Raised every year since IPO; $0.50 → $0.53/quarter (declared Dec-2025, +6%); roughly tripled since 2019; payout ~33%; yield ~2.5% at $79. Well-covered, conservative, with ample reinvestment room.

Incentive alignment (2026 proxy). The annual incentive plan is gated on revenue + adjusted diluted EPS + free cash flow. The long-term plan: PSUs (50% of LTI) vest on relative TSR vs the S&P 500 Health Care Index (50%) + three-year average operational revenue growth (50%), plus options (20%) and time-vested RSUs. The heavy relative-TSR weight is the single best alignment metric (it pays only for outperformance, not a rising tide), and FCF is in the annual plan — both positives. The gap: there is no explicit ROIC/return-on-capital hurdle anywhere, and revenue growth appears in both the annual plan and the PSU, mildly incenting top-line over capital efficiency. For a 24%-ROIC moat business that is a real (if common) weakness, partly mitigated by the relative-TSR weight. CEO Kristin Peck’s FY2025 total comp was $19.0M (pay ratio 236:1); say-on-pay passed at 91%. There has been no CEO/CFO transition (Peck and CFO Wetteny Joseph remain); the R&D head, Rob Polzer, retired in Feb-2026 (succeeded by Kevin Esch).

Insider behavior — a genuine, if small, contrarian signal. Three directors bought stock in the open market (code P) at the May lows: Chairman Michael McCallister (3,000 sh @ $77.76, May-11), former Pfizer CFO Frank D’Amelio (6,650 sh @ $75.39, May-13), and Paul Bisaro (2,000 sh @ $75.88, May-13). These are rare conviction signals (~$0.9M combined), clustered at the bottom. No officer bought, and CEO Peck’s activity is routine option-exercise-and-sell into prior strength. The net insider read is mildly positive — discretionary buys at the lows, no selling into the crash.

Verdict: management has allocated capital intelligently on the operating and strategic axes (organic reinvestment, highest R&D intensity, disciplined M&A, smart pruning, an upgraded balance sheet, a growing covered dividend) — and unintelligently on buyback timing (record dollars at peak multiples right before the crash, with no ROIC hurdle in the comp plan to discourage it). Net grade: B+ — a disciplined operator and an undisciplined repurchaser-at-the-top. The forward test is whether they buy back aggressively at today’s trough.

8. Changes and Headwinds — Last Two Years

The dominant changes are negative, and they are why the stock is where it is.

• Two earnings-driven crashes. Nov-4-2025 (−13.8%): a Q3 EPS beat overshadowed by a full-year revenue guide cut and the first admission of three straight quarters of declining therapeutic vet visits and intensifying derm/parasiticide competition; BofA downgraded. May-7-2026 (−21.5%): a Q1 EPS miss ($1.53, ~−5.6% vs consensus) plus a FY2026 guide cut (to +2–5% revenue / $6.85–7.00 EPS) issued just three months after the original +3–5% / $7.00–7.10 guide, with US companion −11%, derm −13%, Librela −22%, and management abandoning its “competition is transitory” framing for a defensive cost-and-productivity program.
• A credibility problem. Two guidance cuts in six months — including a cut to a guide barely a quarter old — have shredded the “durable 8% compounder” narrative. The fiscal-calendar change that shifted ~$100M between quarters muddied comparability at the worst possible time.
• A structural step-up in competition. Zenrelia and a forthcoming Merck IL-31 mAb in derm; Credelio Quattro and NexGard Plus in parasiticides; generics on Convenia and Cerenia — and, for the first time, management conceding these entrants are not expanding the overall market (i.e., the historical cushion is gone).
• A safety/regulatory overhang. The Librela FDA adverse-event file (3,674 reports, 800+ deaths by 2024; a late-2024 vet alert; ongoing label updates) capping the prior breakout growth product.
• New securities litigation. Multiple securities-fraud class actions filed after the May-7 drop (lead-plaintiff deadline July-27-2026), alleging misleading statements about competition and demand. Scope and merit are unknown; the financial exposure is likely modest relative to the market-cap loss, but it is a fresh overhang.
• Genuinely good portfolio moves (the offset). The 2024 MFA divestiture sharpened the livestock mix (livestock then grew double-digit and partly offset US companion weakness); diagnostics tuck-ins build a growth adjacency; the balance sheet was upgraded to A3/BBB+.

Verdict: on balance these developments WEAKEN the thesis. The portfolio moves are good and are the reason the consolidated decline was not worse, but the dominant changes — a structural competitive step-up across the two largest companion franchises, a safety overhang on the third, two guidance cuts destroying credibility, valuation-insensitive buybacks into a falling knife, and now litigation — are the negatives that justify a de-rating. The open question is whether they justify this de-rating (to the 1.2nd percentile of history) or whether the market has extrapolated a cyclical-plus-competitive air-pocket into permanent decline.

9. Risk Analysis (Risk Matrix)

The risk profile is dominated by growth/competition risk, not financial or existential risk. There is no realistic path to a catastrophic loss (investment-grade, cash-generative, diversified); the real risk is that the bull’s “cyclical air-pocket” is in fact the bear’s “structural decline,” in which case 13x is fair and the stock is dead money rather than impaired.

10. Valuation Discussion (Embedded Expectations)

No price target, no recommendation — embedded-expectations and scenarios only.

The de-rating is the entire story. ZTS has never been this cheap as a public company:

The multiple has compressed from a ~25–40x “untouchable compounder” range to ~13x trailing / ~11.4x forward — the 1.2nd percentile of its own 13-year history (P/E 0.5th, P/S 0.5th, P/B 2.6th, per AZI’s own-history index).

Cross-sectional comps (live, recomputed at current prices):

The cross-sectional tell: the highest-margin, highest-ROIC, most-diversified name in the complex now trades at a lower EV/EBITDA than levered, 6%-margin Elanco and sub-scale Phibro, below big-pharma Merck, and at roughly one-third of IDEXX. The market is explicitly refusing to pay ZTS any premium-to-peers — historically it commanded the largest.

Embedded expectations (reverse math). At an EV of ~$39.7B on ~$2.3–3.0B of sustainable FCF (EV/FCF ~13–17x), and a ~9% cost of equity for a beta-0.7 quality name, the market is pricing perpetual FCF growth of roughly 2–3.5% — i.e. low-single-digit nominal, below the ~6% operational growth ZTS still posts and far below its decade history. Equivalently, ~9.8x EV/EBITDA on a 38%-margin, 24%-ROIC franchise implies the market has stopped underwriting any durable growth premium at all. The bet for a bull is mean-reversion of expectations (and therefore the multiple), not heroic numbers; the bet for a bear is that LSD growth is the new normal and 13x is fair.

Scenario bands (no point target).

The asymmetry: the bear band sits roughly at or just below today’s price, while base and bull sit materially above — and the upside is leveraged to the re-rating, not heroic numbers (even modest multiple normalization toward mid-teens delivers most of the return). This is the classic fallen-quality shape: largely-realized fundamental downside, large optionality on an expectation reset. The risk is that the bear case is right and the stock is dead money at a fair 13x — which is why the falsification tests in “What Must Be True” matter.

11. Variant Perception

Consensus belief. The narrative has flipped from “untouchable secular compounder” (the 2018–2021 25–40x regime) to “broken growth story.” Sell-side is split — a “Moderate Buy” tape with scattered price targets (reported as context only, never our target) — but conviction has collapsed since the Q1-2026 miss. The crowd’s working thesis: US pet demand has structurally softened, pricing power is eroding under new competition, and the premium multiple was never justified.

Strongest bull case. The cheapest-ever (1.2nd-percentile) wide-moat quality name in healthcare; the deceleration is a cyclical/post-pandemic air-pocket, not a structural impairment; ROIC is rising (24%) and margins are at records (38%) — the franchise is intact, only the multiple broke; pet medicalization is a multi-decade tailwind; the mAb and parasiticide pipelines are genuine growth vectors; and management is now positioned to buy back stock at a trough. You are paying ~11x forward for a 24%-ROIC compounder.

Strongest bear case (value trap). 13x is fair, not cheap, because EPS growth has actually stalled and faces structural headwinds: real competition in derm (Apoquel) and parasiticides (Simparica) from rivals and generics; Apoquel LOE ~2029 and Simparica patent ~2032; a Librela safety overhang capping the flagship; and pricing power eroding as price-sensitive owners trade down. If operational growth settles at LSD, a 13x multiple is appropriate and the de-rating is correct, not an overshoot.

The 3–5 assumptions that matter most, with falsifiers:

1. Is US companion softness cyclical or structural? Bull falsified if US companion organic stays ≤LSD for 4+ consecutive quarters; bear falsified if it re-accelerates to MSD–HSD as vet visits normalize.
2. Does pricing power survive competition + LOE? Bull falsified if gross margin rolls below ~70% or price/mix turns negative; bear falsified if margin holds ≥38% operating through the Apoquel/Simparica competition.
3. Can the pipeline replace LOE revenue? Bear falsified if Librela/Solensia + new launches sustain a growing >$1B franchise with no further safety setbacks; bull falsified if Librela safety forces label changes / continued declines.
4. Re-rate or permanent re-rating? Bull falsified if the stock stays ≤14x through two quarters of stabilized growth (the market won’t re-rate); bear falsified if the multiple expands toward mid-teens on stabilization.

Factor-positioning read (from the price/factor work). The factor model classifies ZTS as a low-beta (0.69–0.85), positive-Quality (+0.33) name whose nearest neighbors are wide-moat and min-vol ETFs (VanEck MOAT, USMV, VHT, PPH) and Alcon — a fallen-quality/min-vol profile, not a high-beta cyclical blow-up. But the tape has not confirmed: relative strength is −51% (12m), the stock sits ~33% below its 200-EMA, and it was making lower lows into mid-June after the −21.5% May capitulation. The central divergence is that price and momentum are collapsing while fundamentals (ROIC 24%, op margin 38%, FCF ~$2.3B) are stable-to-improving — the textbook over-punished-quality signature. The honest caveat: such names can stay falling knives until momentum confirms, and there is no basing signal yet. This is quality at a trough multiple with unconfirmed price — evidence that consensus is offsides on the business, not yet a signal that the stock has bottomed.

12. Fact vs. Interpretation Table

13. Open Questions

1. Cyclical or structural? Did US companion-animal visits (cyclical) or Zoetis-specific share loss (structural) drive most of the derm/parasiticide decline? Management insists share losses are limited; BofA and other skeptics believe competition is structural and worsening. Management commentary here is a hypothesis, not evidence — unresolved until 2–3 more quarters of share data.
2. Is the +2–5% FY2026 guide conservative enough? Q1 ran ~−5% organic ex the calendar shift; the implied 2H ramp looks aggressive. Another cut would be the third in a year and would deepen the credibility hole.
3. Will management buy back counter-cyclically now? They have $6B authorized and the cheapest multiple in history — the single most informative forward capital-allocation signal.
4. How does the Librela safety file resolve? Further FDA label action versus stabilization-and-recovery (with Lenivia/Portela) materially changes the OA-pain franchise value.
5. Securities-litigation exposure (July-2026 lead-plaintiff deadline) — scope and merit unknown.
6. Apoquel/Simparica LOE erosion pace — will animal-health’s historically slow generic erosion hold, or has the corporatized/e-commerce channel changed that?

14. What Must Be True

Bull case — what must be true: US companion-animal demand is in a cyclical air-pocket that normalizes within 2–4 quarters; ZTS’s pricing power survives the new derm/parasiticide competition (gross margin holds ≥70%); the mAb/parasiticide pipeline (Librela recovery + Lenivia/Portela + Simparica defense) sustains a growing franchise through the Apoquel LOE; and the market re-rates the multiple back toward the mid-teens as growth stabilizes. Falsification test: US companion-animal organic growth stays ≤LSD for four-plus consecutive quarters and/or gross margin falls below ~70% — either would confirm structural decline and pricing-power erosion, validating the value-trap thesis and the 13x multiple as fair.

Bear case — what must be true: the US companion softening is structural (a permanently lower medicalization growth rate), competition permanently compresses derm/parasiticide pricing and share, Apoquel LOE (2029) and Simparica (2032) erode meaningfully, and ROIC/margins eventually follow revenue down — so 13x is fair and the stock is dead money. Falsification test: two consecutive quarters of stabilizing-to-positive US companion-animal organic growth with operating margin held ≥38% — would confirm the stall was a cyclical air-pocket in an intact compounder and that the de-rating was an overshoot.

15. Source Appendix

See the Source Appendix below for the full citation list. Primary sources: Zoetis 10-K filings FY2021–FY2025 (CIK 0001555280); 10-Q (Q1-2026); DEF 14A proxy statements (2025, 2026); Form 4 insider filings (2024–2026); 8-K material-event filings (2024–2026); Zoetis Q3-2025 (2025-11-04), Q4/FY2025 (2026-02-12), and Q1-2026 (2026-05-07) earnings-call transcripts and press releases. Quantitative data: ROIC.ai (financials, ratios, enterprise value), price history and own-history valuation percentiles, and a public factor model (factor loadings, risk-adjusted track record). Industry/competitive: FDA CVM Librela adverse-event materials; Elanco Zenrelia/Credelio Quattro and Boehringer NexGard Plus press releases; animal-health market data (Grand View/GMInsights); vet-corporatization data. All material numbers reconciled to filings; the filing wins on any discrepancy.

This article’s main body takes no investment position and contains no price target; the only position and valuation zone appear in the clearly-labeled Claude’s Take block at the top, which is the author’s own opinion and general information only — not investment advice.

APPENDIX A — Standard Diligence Questionnaire

Zoetis Inc. (NYSE: ZTS) — as of 2026-06-19

Supplemental to the main article. Fact/Interpretation/Assumption labels applied where it matters.

General

What thoughtful questions have other investors asked about this company? The dominant question since late 2025 is whether the growth deceleration is cyclical (a post-pandemic US vet-traffic/pet-spending air-pocket) or structural (a permanently lower medicalization growth rate plus real competitive erosion in dermatology and parasiticides). Related: Is ZTS’s historically slow generic erosion about to break (Apoquel LOE ~2029, Simparica ~2032)? Can the Librela osteoarthritis-pain franchise recover from its FDA adverse-event overhang? Is the 13x P/E a generational entry into a wide-moat compounder or a value trap on stalled earnings? And will management redirect its (mistimed) buyback to repurchase counter-cyclically at the trough? Skeptics (e.g., BofA) pushed back hard on management’s “competition is transitory” framing through 2025; the May-2026 guidance cut largely vindicated the skeptics on timing.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Neither margin-wise — margins and ROIC are at record highs (gross 71.8%, operating 38.0%, ROIC ~24% in 2025). This is critical: earnings are not cyclically depressed; the problem is growth, not a margin trough. Interpretation: the risk is the opposite of the usual cyclical-trap — the market fears these record margins are unsustainable as competition bites, not that depressed earnings will recover.

Driven by the external environment or internal actions? Both. Margins reflect internal pricing power and mix (companion-animal pharma, MFA divestiture); the revenue stall reflects external forces (US consumer pressure, vet traffic, competitor launches) plus internal stumbles (Librela safety, guidance credibility).

How stable are revenues? Historically very stable and repeat-purchase-driven (chronic-condition refills, vaccine cycles), but 2025–26 revealed more cyclicality than believed — US revenue went from +11% (2024) to flat (2025), with US companion −11% in Q1-2026.

Outlook for products/services? Mixed: parasiticides and international growing; dermatology decelerating under competition; OA-pain mAbs recovering off a low base; livestock higher-margin post-divestiture; diagnostics small but growing.

How big will this market be — growing, shrinking, domestic or international? The global animal-health market (~$45–65B) grows mid-single-digit through-cycle (vendor figures of ~10% are optimistic); companion animal is the larger/faster pool. Roughly 54% US / 45% international for ZTS, with international currently the faster grower. Long-term pet-medicalization tailwind intact but slower and more cyclical than the 2018–2021 consensus assumed.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More. A decade of ~24% ROIC has pulled in competitive supply — Elanco Zenrelia/Credelio Quattro, Boehringer NexGard Plus, a forthcoming Merck IL-31 mAb, and generics on older blockbusters (Convenia, Cerenia). This is the Marathon capital-cycle down-leg.

How profitable is the business (ROIC, ROE)? Exceptional: ROIC ~24%, ROE ~21% (understated by buyback-shrunken equity), gross margin ~72%, operating margin ~38% — all top-decile in healthcare.

How profitable is the industry — competitors, barriers to entry? A consolidated oligopoly (top-5 ~40%; ZTS ~28% of companion drugs) with high barriers (scale, R&D, regulatory know-how, vet relationships, manufacturing). Structurally one of the better healthcare sub-sectors (cash-pay, no PBM, weak historical generic erosion) — but barriers are being tested at the product level.

Can the business be easily understood? Yes — branded animal-health products sold through vets, with chronic-condition refill economics. Straightforward relative to most pharma.

Can it be undermined by foreign low-cost labor? Not meaningfully — the moat is in branded IP, regulatory approvals, and vet distribution, not labor cost. Generic/competitive pressure is the relevant threat, not offshoring.

Do brands matter? Yes — decisively. The vet prescribes/dispenses by brand and owners follow; brand + the agency relationship is the core of the pricing power. But brand strength is product-specific and weakening at the edges (Apoquel) as price transparency rises.

Nature of competition? Increasingly price- and product-feature-based in companion (combination parasiticides, “superior” derm claims), with aggressive discounting/sampling by new entrants. Vaccines and livestock more stable.

Customers’ switching costs? Modest — a vet can switch a patient at the next visit, and on price some are. Lower than enterprise software; this is captivity-via-habit, not lock-in.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — the brand/IP/vet-relationship intangibles that drive ~24% ROIC are largely internally generated and not capitalized (R&D is expensed). Book equity ($3.3B) badly understates economic value; P/B is meaningless here.

Off-balance-sheet liabilities? None material flagged. Standard operating leases; the Librela securities litigation and any product-liability tail are contingent, not yet quantified (Open Question).

How conservative is the accounting? High quality — clean cash conversion (5y OCF/NI ~1.05x), minimal one-time items, modest GAAP-to-adjusted bridge (~$174M, mostly amortization). One flag: the FY2026 fiscal-calendar alignment shifted ~$100M between quarters and flattered the Q1-2026 headline — a comparability (not integrity) issue.

How CapEx-hungry is the business? Light — capex ~6.6% of sales (2025) and declining from an ~8.6% manufacturing-build peak (2023) toward D&A; asset-light branded-pharma economics.

Capital Allocation & Management

How much FCF, and how is it used? ~$2.3B FCF (2025, ~24% margin). Uses: buybacks ($3.2B in 2025, the priority), dividends ($0.9B), small bolt-on M&A, and R&D reinvestment (~$700M). Interpretation: the philosophy is “reinvest organically at high ROIC, return the rest” — sound in principle, but 2024–25 buybacks were executed at peak prices right before the crash.

Significant acquisitions recently? No large deals — a disciplined organic grower (only >$1B deal ever is Abaxis, 2018, ~$2B, well-integrated). Recent activity is tuck-ins (Veterinary Pathology Group 2025; Neogen genomics ~$160M announced 2026) and a divestiture (MFA, 2024). Marathon-favorable: no high-return-chasing asset-growth binge.

Buying back shares? Yes, aggressively — diluted shares 481.8M (2019) → 443.8M (2025), with SBC tiny (~$83M), so buybacks are net-accretive. The critique is timing: record dollars at ~$160–180 just before the −67% drop.

Issuing large amounts of stock to insiders? No — SBC is <0.9% of revenue; dilution is minimal.

Compensation policy of directors/management? CEO Peck $19.0M (pay ratio 236:1); say-on-pay 91%. Annual bonus on revenue + adjusted EPS + FCF; LTI PSUs on relative TSR (50%) + 3-yr operational revenue growth (50%). Interpretation: reasonably aligned (heavy relative-TSR weight is a plus) but no explicit ROIC hurdle, and revenue appears in both plans — a mild empire-building tilt.

Motivations of management? Professional managers (no founder); no CEO/CFO change. Insider ownership is low (~0.5%), but three directors (incl. the Chairman) made rare open-market purchases at the May lows — a genuine conviction signal.

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No — a US C-corp common stock (NYSE: ZTS); standard 1099 dividend treatment.

Dividend policy? ~33% payout; raised every year since IPO ($0.53/quarter, ~$2.12/yr declared); ~2.5% yield at $79; well-covered.

How profitable is the business? Among the most profitable in healthcare (see above).

Is net income diverging from cash from operations? No — OCF tracks/exceeds NI (5y ~1.05x); earnings quality is high.

Risks & Downside

What factors would cause the stock to decline (further)? Another guidance cut (the third in a year); gross-margin erosion confirming lost pricing power; continued US companion declines confirming structural (not cyclical) weakness; adverse Librela FDA label action; faster-than-expected Apoquel/Simparica generic erosion; a negative litigation development.

Risk of a catastrophic loss? Very low — investment-grade (A3/BBB+), ~1.65x net leverage, ~18x interest coverage, ~$2.3B FCF, diversified across species/geographies/categories. No solvency risk.

Chance of a total loss? Negligible. The realistic downside is a value-trap “dead money at a fair 13x” outcome (bear band ~$60–75), not impairment of the enterprise.

Recent News & Events

Has the business environment changed recently? Yes, materially — a structural step-up in companion-animal competition (Zenrelia, Credelio Quattro, NexGard Plus, generics), softer US vet traffic, a Librela safety overhang, and two guidance cuts (Nov-2025, May-2026). These drove the two earnings-day crashes (−13.8%, −21.5%) and the ~67% drawdown.

Significant acquisitions? Only small tuck-ins (Neogen genomics announced 2026; Veterinary Pathology Group 2025) and the 2024 MFA divestiture.

Change in accounting policies? Yes — a fiscal-year-alignment change for ex-US subsidiaries (eliminating a one-month lag) that shifted ~$100M between Q4-2025 and Q1-2026; a comparability issue, not an integrity one.

Recent changes — new markets, facilities, management? R&D head Rob Polzer retired (Feb-2026; succeeded by Kevin Esch); CEO (Kristin Peck) and CFO (Wetteny Joseph) unchanged; a new cost-and-productivity program launched May-2026; manufacturing capacity built out 2022–23 now ramping. Securities class actions filed post-May-2026 (lead-plaintiff deadline July-27-2026).

APPENDIX B — Source Appendix

Zoetis Inc. (NYSE: ZTS) — Research as of 2026-06-19

Sources are grouped by type, primary-first. Every material number reconciles to a primary filing; third-party data aggregators were used for speed and cross-checks and are labeled as such. The filing wins on any discrepancy.

Primary — SEC filings (Zoetis Inc., CIK 0001555280; mirrored locally in output/ZTS/sources/)

1. Form 10-K, FY2025 (filed 2026-02-12, zts-20251231.htm) — segment/category/franchise revenue, margins, risk factors, debt, R&D, capex.
2. Form 10-K, FY2024 (filed 2025-02-13); FY2023 (2024-02-13); FY2022 (2023-02-14); FY2021 (2022-02-15) — multi-year trend reconciliation.
3. Form 10-Q, Q1-2026 (filed 2026-05-07) — Q1 segment/species revenue, the ~$100M fiscal-alignment shift, balance sheet.
4. DEF 14A proxy statements: 2026 (filed 2026-04-08, zts-20260406.htm) and 2025 (filed 2025-04-09) — incentive metrics (AIP: revenue + adjusted EPS + FCF; LTI PSU: relative TSR + 3-yr operational revenue growth), CEO comp ($19.0M), pay ratio (236:1), say-on-pay (91%).
5. Form 4 insider filings (2024–2026) via EDGAR — director open-market purchases (McCallister 3,000 @ $77.76 on 2026-05-11; D’Amelio 6,650 @ $75.39 on 2026-05-13; Bisaro 2,000 @ $75.88 on 2026-05-13); routine officer option-exercise-and-sell activity.
6. Form 8-K material events (2024–2026): Q3-2025 earnings (2025-11-04), Q4/FY2025 earnings (2026-02-12), Q1-2026 earnings (2026-05-07), dividend raises (2024-12-12, 2025-12-11), senior-notes issuance (Aug-2025), Neogen acquisition announcement (2026-02).

Primary — earnings-call transcripts (via ROIC.ai)

7. Q1-2026 earnings call, 2026-05-07 — FY2026 guidance cut (+2–5% revenue / $6.85–7.00 adj EPS); US companion −11%, derm −13%, Librela −22%; the ~$100M calendar shift; cost-and-productivity program; management’s revised competition framing.
8. Q4/FY2025 earnings call, 2026-02-12 — FY2025 results; original FY2026 guide (+3–5% / $7.00–7.10).
9. Q3-2025 earnings call, 2025-11-04 — FY2025 revenue guide cut; admission of three quarters of declining therapeutic vet visits; R&D leadership change.

Quantitative data aggregators (cross-check; reconciled to filings)

10. ROIC.ai — income statement, balance sheet, cash flow, profitability ratios (ROIC/ROE/margins), enterprise value, valuation multiples for ZTS and comps (IDXX, ELAN, PAHC, MRK). TTM figures ending 2026-03-31.
11. AZI (azitrading.com) — five-year daily price history (adjusted OHLCV, EMAs, beta) and the valuation_index own-history percentile ranks (composite 1.2 pctile; P/E 0.5; P/S 0.5; P/B 2.6).
12. FactorsToday (factorstoday.com/api) — factor loadings (beta ~0.69–0.85; Quality +0.33; SmallSize +0.45), risk-adjusted leaderboard (y1 −48.5%, y3 −21%/yr, y5 −15%/yr, y10 +6%/yr; max drawdown −68.5%), idiosyncratic vol (30.7%), relative strength (rs_12m −50.6), and factor-similar peers (VanEck MOAT, USMV, VHT, PPH; Alcon).

Industry, competitive & regulatory (public secondary)

13. FDA Center for Veterinary Medicine — Librela (bedinvetmab) adverse-event materials and veterinarian alert (2024–2025); AVMA reporting on ~3,674 adverse events / 800+ death reports.
14. Elanco press releases — Zenrelia (ilunocitinib) launch and head-to-head claims (Sept-2024); Credelio Quattro launch (Jan-2025).
15. Boehringer Ingelheim — NexGard Plus combination parasiticide.
16. Patent data (Apoquel US compound patent ~2029; Apoquel Chewable formulation patents extending later; Simparica Trio ~2032) — public patent databases / company disclosure.
17. Animal-health market sizing and growth — Grand View Research / GMInsights (2025); US veterinary-practice corporatization data (Today’s Veterinary Business and industry sources).
18. Dated price-reaction and guidance coverage — MarketBeat, Yahoo Finance/Zacks, Motley Fool, Investing.com (Nov-2025 and May-2026 earnings reactions); Business Wire (securities class-action notices, June-2026); Macrotrends (price history cross-check).
19. Rating actions — Moody’s upgrade to A3 (Jan-2025); S&P upgrade to BBB+ (2025).

Quantitative aggregator data (items 10–12) and management commentary (items 7–9) are treated as hypotheses to validate, not primary evidence; all material figures are reconciled to the SEC filings (items 1–6). No analyst price target or rating from any third party was used to form the views in this article.